Publications by authors named "L V Chichanovskaya"
[Significance of immunological markers in patients with obstructive sleep apnea and comorbid pathology].
Zh Nevrol Psikhiatr Im S S Korsakova
September 2024
Article Synopsis
- The study aimed to investigate the role of immunological markers in patients with obstructive sleep apnea (OSA) and accompanying health issues by comparing two groups: one with OSA and one without.
- Results showed higher levels of certain markers (GFAP, BDNF, antibodies to acetylcholine receptors) and indicators of depression and drowsiness in OSA patients, suggesting cognitive impairments linked to these markers.
- The findings indicate that neuromarkers like GFAP and BDNF are associated with cognitive dysfunction in OSA, with elevated acetylcholine receptor antibodies possibly pointing to neuromuscular issues and emotional problems, particularly depression and fatigue, worsening as OSA severity increases.
[Clinico-psychological profile and life quality of patients with post-COVID syndrome].
Zh Nevrol Psikhiatr Im S S Korsakova
April 2023
Objective: To study clinico-psychological profile and life quality of patients with post-COVID syndrome.
Material And Methods: We examined 162 patients aged 24-60 years with confirmed SARS-CoV-2 infection which having symptoms that served as the basis for the diagnosis of post-COVID syndrome. Patients underwent general neurological and somatic examination with allocation of the corresponding neurological syndromes.
Objectives: To evaluate efficacy, safety, and tolerability of the treatment with teberif/interferon β-1a, to analyze safety, tolerability and dynamics of key efficacy variables after switching from referent drug rebif to biosimilar teberif in patients with remitting multiple sclerosis (RMS).
Material And Methods: During the main period of the international multicenter randomized study patients were randomized to receive treatment with teberif for 52 weeks, or rebif for 52 weeks, or placebo for 16 weeks to evaluate efficacy and safety of treatment. After the main study period, patients were group-independently switched to take open-label teberif treatment during the next 48 weeks.
[Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)].
Zh Nevrol Psikhiatr Im S S Korsakova
March 2019
Aim: To study an effect of cortexin on neurological symptoms and oxidative stress as part of the ischemic cascade in chronic cerebral ischemia (CCI), I-II stages.
Material And Methods: The multicenter randomized controlled study included 189 patients with CCI, 42 (22.2%) men and 147 (77.
[A study of the efficacy and safety of L-carnitine in patients with ischemic stroke in the early rehabilitation period].
Zh Nevrol Psikhiatr Im S S Korsakova
April 2019
Aim: To evaluate the efficacy and safety of L-carnitine injections in patients with ischemic stroke (IS) in the rehabilitation period.
Material And Methods: Sixty patients in the early rehabilitation period of IS were stratified into two groups. Patients of group 1 received elcar, the 100 mg/ml solution for intravenous and intramuscular injection, in dose of 500 mg intramuscular 2 times a day during 7 days, with the second course after 10 days, in the complex treatment of the 2 stage of poststroke rehabilitation.